Clinical trials: Anti-PD-1
Bladder Urothelial Carcinoma
Safety and Efficacy of Toripalimab for Patients With Locally Advanced or Metastatic Bladder Urothelial Carcinoma
This is a multi-center, open-label, phase 2 study evaluating the humanized anti-PD-1 antibody JS001, as a monotherapy in patients with locally advanced or metastatic bladder urothelial carcinoma who have failed in routine…
- Trial name
- NCT03113266
- Testing
- humanized anti-PD-1 monoclonal antibody toripalimab
- Where
- China
- Volunteers
- 370 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Melanoma, Non-Small Cell Lung Cancer
POINTING: Clinical Cohort Study of Patients With Melanoma and NSCLC Receiving Checkpoint Inhibitors
This is a two-center, prospective continuously accruing longitudinal cohort study in patients with non-small cell lung carcinoma (NSCLC) or metastatic melanoma eligible for standard anti-PD-1 antibody treatment.
- Trial name
- POINTING (NCT04193956)
- Testing
- Standard-of-care procedures, Study procedures
- Where
- 2 sites in Netherlands
- Volunteers
- 3,500 people
- Sponsor
- University Medical Center Groningen
Toxicity, Drug, Adverse Drug Event
TIL and Anti-PD1 in Metastatic Melanoma
The ACTME study is an investigator initiated, single center phase I/II clinical trial for patients with progressive unresectable stage III or stage IV melanoma.
- Conditions
- Toxicity, Drug, Adverse Drug Event, Effects of Immunotherapy
- Trial name
- ACTME (NCT03638375)
- Testing
- Nivolumab & Tumor Infiltrating Lymphocytes with/without Interferon-Alpha
- Where
- Netherlands
- Volunteers
- 34 people
- Sponsor
- Leiden University
Advanced Malignant Solid Neoplasm, Anal Carcinoma
Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
This phase I trial studies the side effects and best dose of nivolumab when given with ipilimumab in treating patients with human immunodeficiency virus (HIV) associated classical Hodgkin lymphoma that has returned after a period…
- Conditions
- Advanced Malignant Solid Neoplasm, Anal Carcinoma, HIV Infection, Kaposi Sarcoma
- Trial name
- NCT02408861
- Testing
- Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography
- Where
- 34 sites in United States, Australia
- Volunteers
- 79 people
- Sponsor
- National Cancer Institute (NCI)
C-staged Hepatocellular Carcinoma in BCLC Classification
A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab Versus Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification
This study was designed to evaluate the effectiveness and safety of hepatic arterial infusion chemotherapy combined with Apatinib and Camrelizumab (treatment group) versus Apatinib and Camrelizumab (control group) for C-staged…
- Trial name
- TRIPLET-III (NCT05313282)
- Testing
- Hepatic Arterial Infusion combined with Apatinib and Camrelizumab, Apatinib combined with Camrelizumab
- Where
- 5 sites in China
- Volunteers
- 140 people
- Sponsor
- Sun Yat-sen University
Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
SBRT Combined With AK104 to Treatment Relapsed or Metastatic ESCC
The entire treatment process is divided into two phases: Phase I SBRT combined with PD-1/CTLA-4 bispecific antibody (AK104) and Phase II AK104 single-agent maintenance therapy.
- Trial name
- NCT05732662
- Testing
- SBRT, Cadonilimab
- Volunteers
- 25 people
- Sponsor
- The First People's Hospital of Changzhou
Head & Neck Cancer, Head & Neck Squamous Cell Carcinoma
Impact of Early Response to First-line Anti-PD-1 Monotherapy in Patients With Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma, Assessed by 18F-FDG PET/CT
This study aims to evaluate the role of early response assessment by 18F-FDG PET/CT in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma with PD-L1 CPS >1 treated with pembrolizumab…
- Trial name
- PEMBRO-PET (NCT07448727)
- Where
- Italy
- Volunteers
- 25 people
- Sponsor
- University of Rome Tor Vergata
Cervical Cancer, Cervical Cancer Metastatic
Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy and Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer (CAESURA)
This is a multicenter, open-label, single-arm study of efficacy, safety and pharmacokinetics of BCD-100 (JSC BIOCAD, Russia) in combination with platinum-based chemotherapy and bevacizumab as first-line treatment in patients with…
- Conditions
- Cervical Cancer, Cervical Cancer Metastatic, Cervical Cancer Recurrent
- Trial name
- NCT03912402
- Testing
- BCD-100, Bevacizumab, Paclitaxel
- Where
- 24 sites in Russia
- Volunteers
- 49 people
- Sponsor
- Biocad
Cervical Cancer
A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer
The purpose of this study is to assess the efficacy and safety of HLX10(Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection) plus chemotherapy compared to the efficacy and safety of placebo plus chemotherapy in the…
- Trial name
- NCT04806945
- Testing
- HLX10, Paclitaxel, Cisplatin
- Where
- China
- Sponsor
- Shanghai Henlius Biotech
Metastatic Colon Cancer, Solid Tumor
Pembrolizumab + Poly-ICLC in MRP Colon Cancer
The main purpose of this study is to determine the dose of poly-ICLC that is safe and tolerable when it is combined with pembrolizumab in patients with colon cancer.
- Trial name
- NCT02834052
- Testing
- pembrolizumab, Poly-ICLC
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Asha Nayak
Gastric Adenocarcinoma, Esophageal Squamous Cell Carcinoma
The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC
The purpose of this study is to preliminarily evaluate anti-tumor activity of a Recombinant Humanized Anti-PD-1 Monoclonal Antibody for Infusion (JS001) in treating advanced gastric adenocarcinoma, esophageal squamous cell…
- Conditions
- Gastric Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Nasopharyngeal Carcinoma, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT02915432
- Testing
- 3 mg/kg anti-PD-1 mAb JS001 Q2W, 360 mg anti-PD-1 mAb JS001 Q3W, 240mg anti-PD-1 mAb JS001 Q3W
- Where
- 23 sites in China
- Volunteers
- 401 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Melanoma, Metastatic Melanoma
Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets
The purpose of this research is to test the safety and effectiveness of the investigational combination of Troriluzole, ipilimumab, and nivolumab, and to learn whether this combination works in treating melanoma that has spread…
- Trial name
- NCT04899921
- Testing
- Ipilimumab, Nivolumab, Troriluzole
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Dana-Farber Cancer Institute
Metastatic Solid Tumor Cancer, Recurrent Head and Neck Cancer
Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer
This is a Phase 1/2 study of the combination of Ad-p53 administered intra-arterially in combination with oral metronomic capecitabine or pembrolizumab in patients with unresectable, refractory liver metastases of colorectal…
- Trial name
- NCT02842125
- Testing
- Ad-P53, Xeloda, Keytruda
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- MultiVir, Inc.
Sarcoma, Soft Tissue
A Phase II Study for 609A in the Treatment of Advanced Undifferentiated Pleomorphic Sarcoma
The main purpose of this study is to evaluate the efficacy and safety of recombinant anti-PD-1 humanized monoclonal antibody injection (609A) in patients with unresectable or advanced undifferentiated pleomorphic sarcoma
- Trial name
- NCT05193214
- Testing
- Recombinant anti-PD-1 humanized monoclonal antibody injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Neoplasm Metastasis, Advanced Tumors
Platform Trial Evaluating Safety and Efficacy of Ezabenlimab Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours
This is a study in adults with various types of advanced cancer. The purpose of the study is to test a medicine called BI 754091 in combination with several other cancer medicines. BI 754091 is an immunotherapy.
- Conditions
- Neoplasm Metastasis, Advanced Tumors, Metastatic Solid Tumors
- Trial name
- NCT03697304
- Testing
- Ezabenlimab, BI 754111, BI 836880
- Where
- 17 sites in United States, Canada and 1 more
- Volunteers
- 211 people
- Sponsor
- Boehringer Ingelheim
Squamous Cell Carcinoma of Head and Neck, Squamous Cell Carcinoma of Head and Neck (SCCHN)
TMV Vaccine Alone or With Toripalimab-tpzi for Recurrent Head and Neck Squamous Cell Carcinoma
The goal of this clinical trial is to learn if an experimental, personalized cancer vaccine called TMV vaccine is safe and to find the best dose to study in future trials.
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Squamous Cell Carcinoma of Head and Neck (SCCHN), HNSCC, Neoplasm Recurrence, Local
- Trial name
- NCT07898124
- Testing
- TMV Vaccine, Toripalimab-tpzi
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Metaclipse Therapeutics Corporation
Head and Neck Cancer
Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients
This is a non-randomized, open-label, Phase Ib study to assess the safety and efficacy of a DNA methyltransferase inhibitor and immune checkpoint inhibitor(s) (durvalumab and/or tremelimumab) combination therapy in the treatment…
- Trial name
- NCT03019003
- Testing
- Oral Decitabine, Durvalumab, 5' Azacitidine
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Massachusetts General Hospital
Metastatic Colorectal Cancer
Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC
The purpose of this study is to evaluate the preliminary efficacy and safety of NIS793 and other novel investigational combinations with standard of care (SOC) anti-cancer therapy vs SOC anti-cancer therapy for the second line…
- Trial name
- daNIS-3 (NCT04952753)
- Testing
- NIS793, Bevacizumab, Modified FOLFOX6
- Where
- 55 sites in United States, Australia and 15 more
- Volunteers
- 204 people
- Sponsor
- Novartis Pharmaceuticals
Head and Neck Squamous Cell Carcinoma
Becotatug Vedotin Combined With Pucotenlimab as Neoadjuvant Therapy for Resectable Recurrent Head and Neck Squamous Cell Carcinoma After Progression on Immunotherapy: A Prospective Phase II Study
This is a prospective, single-arm, multi-center, Phase II clinical trial evaluating the efficacy and safety of neoadjuvant becotatug vedotin (an anti-EGFR antibody-drug conjugate) combined with pucotenlimab (HX008, an anti-PD-1…
- Trial name
- GATEWAY (NCT07589049)
- Testing
- Becotatug Vedotin, Pucotenlimab
- Where
- 12 sites in China
- Volunteers
- 42 people
- Sponsor
- Sun Yat-sen University
Advanced Pancreatic Ductal Adenocarcinoma
ATRA and SDK002 in Combination With Chemotherapy and Anti-PD-1 Inhibitor in Patients With Advanced Pancreatic Ductal Adenocarcinoma.
This study is testing whether adding three drugs, All-Trans Retinoic Acid (ATRA), SDK002 (also called Arsenic Trioxide or ATO), and tislelizumab, to standard chemotherapy is safe for people with advanced pancreatic cancer.
- Trial name
- ATARI-PDAC (NCT07348107)
- Testing
- ATRA, Arsenic Trioxide (ATO), Gemcitabine
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Daniel Breadner
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.